ARID1B and non-small cell lung carcinoma: Naito et al. demonstrated that NSCLC patients with loss of SWI/SNF complex subunit expression (SMARCA4, SMARCA2, ARID1A, or ARID1B) were more likely to have aggressive clinicopathologic features, positive PD‐L1 status, and a high TMB.12